Showing results (61-70 of 79) with videos related to
Sort By:
Pageof 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2015
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trialsK Fizazi, T W Flaig, M Stöckle, et al.Oncogene|July 20, 2007
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancerG Attard, J Clark, L Ambroisine, et al.British Journal of Cancer|February 27, 2015
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agentsM Crespo, G van Dalum, R Ferraldeschi, et al.British Journal of Cancer|July 3, 2008
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancerG Attard, J Clark, L Ambroisine, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 25, 2014
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancerR Leibowitz-Amit, A J Templeton, A Omlin, et al.British Journal of Cancer|March 6, 2008
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumoursS P Blagden, L R Molife, A Seebaran, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 13, 2008
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experienceD Olmos, H-T Arkenau, J E Ang, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2015
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxelK N Chi, T Kheoh, C J Ryan, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2025
Final overall survival and safety analyses of the phase III PSMAfore trial of [<sup>177</sup>Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancerK Fizazi, K N Chi, N D Shore, et al.Oncogene|January 10, 2017
Analysis of DNA methylation in single circulating tumor cellsC F Pixberg, K Raba, F Müller, et al.Pageof 8